FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to the use of potassium osmate salt K2[OsO2(OH)4] with isotope 187Os as a anticancer agent.
EFFECT: salt shows high anticancer activity in system in vivo with no undesired side effects.
Title | Year | Author | Number |
---|---|---|---|
AGENT FOR EHRLICH TUMOUR INHIBITION | 2012 |
|
RU2538716C2 |
PHARMACEUTICAL COMPOSITION ON BASIS OF PEPTIDE POSSESSING ANTITUMORAL ACTION | 2007 |
|
RU2362579C1 |
USE OF THE COMPOUND 2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL ORALLY FOR THE TREATMENT OF MELANOMA B16, EHRLICH TUMOR, SARCOMA 180, SARCOMA 37, LYMPHOSARCOMA LIO-1 AND CARCINOSARCOMA WALKER 256 EXPERIMENTALLY IN MICE AND RATS | 2020 |
|
RU2733643C1 |
METHOD FOR ENHANCING ANTIMETASTATIC ACTION OF CISPLATIN AND REDUCING ITS SIDE EFFECT ON HAEMOSTASIS SYSTEM | 2023 |
|
RU2825825C1 |
PEPTIDE, POSSESSING ANTI-TUMOR AND ANTI-METASTATIC ACTIVITY, AND FINISHED DOSAGE FORM BASED THEREON | 2018 |
|
RU2682039C1 |
2-[3-(2-CHLOROETHYL)-3-NITROSOUREIDO]-1,3-PROPANEDIOL SHOWING ANTITUMOR ACTIVITY | 1992 |
|
RU2068843C1 |
AGENT FOR CORRECTING CYTOTOXIC EFFECTS OF PARANEOPLASTIC PROCESSES AND CHEMOTHERAPY SHOWING ANTICANCER ACTIVITY | 2011 |
|
RU2447888C1 |
METHOD FOR TREATING MALIGNANT NEOPLASMS | 2006 |
|
RU2320364C1 |
ANTI-TUMOR AGENT | 2003 |
|
RU2240793C1 |
ANTITUMOR AGENT | 1998 |
|
RU2128042C1 |
Authors
Dates
2012-07-10—Published
2011-06-02—Filed